Tricyclic JAK1 Inhibitors for Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK inhibitors for treating inflammatory diseases and cancer have limitations in potency, selectivity, and safety, leading to suboptimal therapeutic outcomes due to off-target effects.
Innovation Solution
Development of novel, orally and topically available, selective JAK1 inhibitors with improved safety and efficacy profiles, represented by specific structural formulas (I) and (VII), targeting JAK1 kinase activity to modulate immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current JAK inhibitors are used to treat inflammatory diseases and cancer, then therapeutic effect is achieved, but off-target effects occur leading to reduced safety
Solution Approach 1:
The patent applies local quality by designing JAK1 inhibitors with specific structural features (tricyclic core with particular substituent patterns) that enable selective binding to JAK1 kinase domain while avoiding other JAK family members. The molecular structure is optimized to interact with unique residues in JAK1's ATP-binding pocket, achieving localized specificity at the molecular interaction site.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the inhibitor molecules (substituent types, positions, and configurations on the tricyclic scaffold) to optimize the balance between potency and selectivity. By adjusting these molecular parameters, the compounds achieve enhanced JAK1 inhibition with reduced cross-reactivity toward JAK2, JAK3, and TYK2.
2Power
If JAK1 inhibition is enhanced to improve therapeutic outcomes, then potency increases, but selectivity decreases leading to off-target effects
Solution Approach 1:
The patent applies segmentation by dividing the JAK family into distinct targets and designing inhibitors that specifically address JAK1 while leaving other JAKs unaffected. The molecular structure is segmented to recognize JAK1-specific structural features, creating a selective inhibition pattern that spares JAK2, JAK3, and TYK2 from off-target effects.
Solution Approach 2:
The patent uses the unique structural features of JAK1's kinase domain as an intermediary that mediates selective binding. Specific amino acid residues and structural motifs in JAK1 serve as molecular intermediaries that facilitate high-affinity binding of the tricyclic inhibitors, while the same features are absent or different in other JAK family members, preventing cross-reactivity.
3Productivity
If existing JAK inhibitors are administered, then disease treatment is achieved, but safety is compromised due to side effects
Solution Approach 1:
The patent converts the potential harm of off-target JAK inhibition into a benefit by designing molecules that exploit the structural differences between JAK1 and other JAKs. The inhibitors are structured to recognize and bind selectively to JAK1's unique features, transforming what could be non-specific kinase inhibition into targeted therapy that achieves therapeutic effects while minimizing harmful side effects.
Data Source
AI summary
The invention provides a novel class of therapeutics that are safe and effective inhibitors of Janus kinase 1 and pharmaceutical composition and methods of preparation and use thereof in the treatment of various diseases and disorders (e.g., inflammatory diseases, immune-mediated diseases or cancer).